These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34422119)

  • 21. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Approaches for Immune Directed Treatment for Ovarian Cancer.
    Hardwick N; Frankel PH; Cristea M
    Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.
    Zhang Y; Cui Q; Xu M; Liu D; Yao S; Chen M
    Front Immunol; 2022; 13():901772. PubMed ID: 35833132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
    Post CCB; Westermann AM; Bosse T; Creutzberg CL; Kroep JR
    Crit Rev Oncol Hematol; 2020 Aug; 152():102973. PubMed ID: 32497971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
    Pietzner K; Nasser S; Alavi S; Darb-Esfahani S; Passler M; Muallem MZ; Sehouli J
    J Gynecol Oncol; 2018 Nov; 29(6):e93. PubMed ID: 30207101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors.
    Boutros A; Carosio R; Campanella D; Spagnolo F; Banelli B; Morabito A; Pistillo MP; Croce E; Cecchi F; Pronzato P; Queirolo P; Raposio E; Fontana V; Tanda ET
    Immunooncol Technol; 2023 Dec; 20():100408. PubMed ID: 38192613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
    Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
    Front Immunol; 2021; 12():762989. PubMed ID: 34975854
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Wieser V; Gaugg I; Fleischer M; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Zeimet AG; Fiegl H; Marth C
    Oncotarget; 2018 Apr; 9(25):17501-17511. PubMed ID: 29707124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
    Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
    Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
    Boussios S; Karihtala P; Moschetta M; Karathanasi A; Sadauskaite A; Rassy E; Pavlidis N
    Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31374917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.
    Qiao M; Jiang T; Zhou C
    J Thorac Dis; 2018 May; 10(Suppl 13):S1534-S1546. PubMed ID: 29951304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers.
    Lee EK; Konstantinopoulos PA
    Ther Adv Med Oncol; 2020; 12():1758835920944116. PubMed ID: 32782491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.
    Zhang G; Liu C; Bai H; Cao G; Cui R; Zhang Z
    Oncol Lett; 2019 Mar; 17(3):2583-2591. PubMed ID: 30854033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
    Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
    J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.
    Idel C; Ribbat-Idel J; VON Bernuth A; Fleckner J; Rades D; Kirfel J; Sailer V; Plötze-Martin K; Bruchhage KL; Pries R
    Anticancer Res; 2023 Dec; 43(12):5349-5358. PubMed ID: 38030173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.